Sei Investments Co. decreased its holdings in shares of Privia Health Group, Inc. (NASDAQ:PRVA – Free Report) by 69.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 140,370 shares of the company’s stock after selling 320,283 shares during the quarter. Sei Investments Co.’s holdings in Privia Health Group were worth $2,887,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Durable Capital Partners LP boosted its stake in Privia Health Group by 1.8% in the 3rd quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock worth $291,123,000 after buying an additional 203,842 shares during the last quarter. State Street Corp increased its stake in shares of Privia Health Group by 1.5% during the 2nd quarter. State Street Corp now owns 4,171,069 shares of the company’s stock valued at $95,935,000 after acquiring an additional 61,853 shares during the last quarter. Van Berkom & Associates Inc. lifted its holdings in shares of Privia Health Group by 5.4% during the 1st quarter. Van Berkom & Associates Inc. now owns 4,053,043 shares of the company’s stock worth $83,371,000 after acquiring an additional 208,787 shares during the period. Geode Capital Management LLC boosted its position in shares of Privia Health Group by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 2,814,290 shares of the company’s stock worth $66,738,000 after acquiring an additional 31,204 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Privia Health Group by 1.6% in the fourth quarter. Principal Financial Group Inc. now owns 2,787,802 shares of the company’s stock worth $66,099,000 after acquiring an additional 43,589 shares during the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Citigroup reaffirmed a “buy” rating on shares of Privia Health Group in a research report on Thursday, July 23rd. Weiss Ratings raised Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 2nd. Zacks Research upgraded Privia Health Group from a “strong sell” rating to a “hold” rating in a report on Wednesday. Barclays lowered their price target on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 26th. Finally, Canaccord Genuity Group set a $32.00 price objective on Privia Health Group in a report on Friday. Eleven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.
Insider Buying and Selling
In other Privia Health Group news, CFO David Mountcastle sold 21,275 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $27.67, for a total value of $588,679.25. Following the transaction, the chief financial officer owned 164,853 shares in the company, valued at $4,561,482.51. The trade was a 11.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Shawn Morris sold 53,722 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $27.24, for a total transaction of $1,463,387.28. Following the completion of the transaction, the director directly owned 68,188 shares of the company’s stock, valued at approximately $1,857,441.12. The trade was a 44.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 452,357 shares of company stock valued at $11,436,655 in the last quarter. Company insiders own 5.70% of the company’s stock.
Key Headlines Impacting Privia Health Group
Here are the key news stories impacting Privia Health Group this week:
- Positive Sentiment: Privia reported second-quarter revenue of $632.6 million, up 21.4% year over year and above the approximately $597.3 million consensus. Net income rose to $9.0 million from $2.7 million, while adjusted EBITDA increased 29.1% to $37.4 million. Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
- Positive Sentiment: Management raised or improved its full-year 2026 expectations across key operating metrics, including attributed lives, practice collections, GAAP revenue, care margin, platform contribution and adjusted EBITDA. Revenue is expected toward the high end of the $2.35 billion-$2.45 billion range, with adjusted EBITDA of $145 million-$155 million. Privia Health Raises 2026 Outlook
- Positive Sentiment: Underlying growth indicators remained strong: implemented providers rose 10.1% to 5,644, value-based-care attributed lives increased 19.2% to 1.647 million, and the adjusted EBITDA margin expanded to 28.3% from 25.2%. Privia Health Q2 2026 Earnings Presentation
- Neutral Sentiment: Zacks upgraded PRVA from “strong sell” to “hold,” signaling reduced downside expectations but not a bullish recommendation. Zacks
- Negative Sentiment: GAAP EPS was $0.07, narrowly below Zacks’ $0.08 estimate. Reported profitability also included $19.4 million of non-cash stock-based compensation, while operating cash flow was negative $48.4 million in the first half, factors that may temper enthusiasm over earnings quality. Privia Health Misses Q2 Earnings Estimates
Privia Health Group Stock Up 2.0%
PRVA opened at $22.45 on Friday. The firm’s 50 day moving average is $24.63 and its 200-day moving average is $23.35. Privia Health Group, Inc. has a 52-week low of $19.53 and a 52-week high of $28.82. The firm has a market capitalization of $2.83 billion, a P/E ratio of 106.91, a P/E/G ratio of 1.74 and a beta of 0.85.
Privia Health Group Company Profile
Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.
Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.
Featured Articles
- Five stocks we like better than Privia Health Group
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Want to see what other hedge funds are holding PRVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Privia Health Group, Inc. (NASDAQ:PRVA – Free Report).
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
